MVIS US Listed Pharmaceutical 25 Index

The modified market cap-weighted index tracks the performance of the largest and most liquid US-listed companies that derive at least 50% of their revenues from pharmaceuticals. The pure-play index contains only companies which are engaged primarily engaged in research (incl. research contractors) and development as well as production, marketing and sales of pharmaceuticals. Pharmacies are excluded. The MVIS US Listed Pharmaceutical 25 Index (MVPPH) has been licensed to underlie financial products with currently USD 227.27 million in assets under management.

Country and Sector Weightings

MVIS Sector Indices are pure-play sector indices. Companies must generate at least 50% of their revenues in the target sector to be eligible for index inclusion. Country and Sector weightings are based on the weightings of all index components in a certain country or sector.

CountryComponentsWeight
Canada1 2.84%
United States12 52.94%
Denmark1 4.40%
France1 4.83%
Ireland2 5.71%
Netherlands1 3.31%
Switzerland1 4.76%
United Kingdom4 12.61%
Israel1 4.25%
Japan1 4.35%
Total25 100.00%
SectorComponentsWeight
Health Care25 100.00%
Total25 100.00%

Size Weightings

  • Large-Cap: companies with a market capitalisation above 6,000 mln USD
  • Mid-Cap: companies with a market capitalisation from 1,500 mln to 6,000 mln USD
  • Small-Cap: companies with a market capitalisation from 200 mln to 1,500 mln USD
  • Micro-Cap: companies with a market capitalisation up to 200 mln USD
SizeMarket CapComponentsWeight
Large-Cap2,214,542,804,200 USD22 96.50%
Mid-Cap8,553,496,600 USD3 3.50%
Small-Cap---
Micro-Cap---
Total2,223,096,300,800 USD25 100.00%
Up